<?xml version="1.0" encoding="UTF-8"?>
<p>The cumulative incidence of non-relapse mortality at 3 years among patients with chronic GvHD was 22% in 1-mMUD recipients, 11% in UCB recipients, and 6% in the Haplo/PTCY recipients, with no statistically significant differences between the three groups [1-mMUD 
 <italic>versus</italic> UCB, HR 0.32 (95% CI: 0.1-1.4), 
 <italic>P</italic>=0.13; 1-mMUD 
 <italic>versus</italic> Haplo/PTCY, HR 0.20 (95% CI: 0.0-1.5), 
 <italic>P</italic>=0.12] (
 <xref rid="t3-1040835" ref-type="table">Table 3</xref>). The cumulative incidence of overall survival at 3 years among patients with chronic GvHD was 72% in 1-mMUD recipients, 82% in UCB recipients, and 90% in Haplo/PTCY recipients, with no statistically significant differences between the three groups [1-mMUD 
 <italic>versus</italic> UCB, HR 0.59 (95% CI: 0.3-1.4), 
 <italic>P</italic>=0.21; 1-mMUD 
 <italic>versus</italic> Haplo/PTCY, HR 0.49 (95% CI: 0.2-1.4), 
 <italic>P</italic>=0.18] (
 <xref rid="t3-1040835" ref-type="table">Table 3</xref>). Progression-free survival after HCT did not differ between the three groups (
 <xref ref-type="fig" rid="f1-1040835">Figure 1B</xref>).
</p>
